Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones

Journal of Medicinal Chemistry

Volumn 43, Issue 16, 2000, Pages 3052-3066

  Oguchi, M ^a   Wada, K ^a   Honma, H ^a   Tanaka, A ^a   Kaneko, T ^a   Sakakibara, S ^a   Ohsumi, J ^a   Serizawa, N ^a   Fujiwara, T ^a   Horikoshi, H ^b   Fujita, T ^a  

^a DAIICHI SANKYO CO   (Japan)

^b Sankyo Pharma Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [4 (5 METHOXY 3 METHYL 3H IMIDAZO[4,5B]PYRIDIN 2 YLMETHOXY)BENZYL]THIAZOLIDINE 2,4 DIONE; ANTIDIABETIC AGENT; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

3T3 CELLS; ADIPOCYTES; ANIMALS; BIOLOGICAL AVAILABILITY; CELL DIFFERENTIATION; DIABETES MELLITUS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HEART; HYPOGLYCEMIC AGENTS; IMIDAZOLES; MALE; MICE; ORGAN SIZE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0034632802     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990522t     Document Type: Article

References (51)

1. Role of insulin resistance in human disease
2. Insulin resistance - Mechanisms, syndromes, and implications
3. Insulin action, diabetogenes, and the cause of type II diabetes
4. Pathophysiology of insulin resistance in human disease
5. Insulin resistance or insulin deficiency: Which is the primary cause of NIDDM?
6. Biochemistry of diabetes
7. The triumvirate: β-Cell, muscle, liver
8. Treatment of non-insulin-dependent diabetes mellitus
9. Exercise and physical training: Effects on insulin sensitivity and glucose metabolism
10. Trends in use of oral hypoglycemic agents: 1964-1986
11. Oral hypoglycemic agents
12. New pharmacological approaches to therapy of NIDDM
13. Drugs on the horizon for treatment of type 2 diabetes
14. New approaches to diabetes
15. Recent advances in the discovery and development of potential antidiabetic agents
16. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes
17. Effect of clofibrate on glucose tolerance in maturity onset diabetes
18. Studies on antidiabetic agents II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives
19. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent
20. Ciglitazone, a new hypoglycemic agent: I. Studies in ob/ob and db/db mice, diabetic chinese hamsters, and normal and streptozotocin-diabetic rats
21. Ciglitazone, a new hypoglycemic agent: II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice
22. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
23. Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and zucker fatty rats
24. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
25. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice
26. In vitro studies on the action of CS-045, a new antidiabetic agent
27. Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4diones as hypoglycemic agents
28. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds
29. The synthesis of BRL 49653 - A novel and potent antihyperglycaemic agent
30. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output
31. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells
32. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
33. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
34. 2 in adipose tissue of high-fat-fed rats
35. A human peroxisome- proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazolidinedione drugs
36. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-γ in human adipocytes
37. The structure-activity relationship between peroxisome proliferator-activated receptorγ agonism and the antihyperglycemic activity of thiazolidinediones
38. Thiazolidinediones and insulin resistance: Peroxisome proliferator-activated receptorγ activation stimulates expression of the CAP gene
39. Inhibition of long chain fatty acid oxidation is not involved in thiazolidinedione induced cardiac hypertrophy
40. Subchronic toxicity of the thiazolidinedione, tanabe-174 (LY282449), in the rat and dog
41. Thiazolidinedione induced cardiac biochemical changes and increased IGF-1 action on cardiomyocytes
42. Metabolite analogues. VII Preparation of some benzimidazolyl analogues of ethyl pteroylglutamate
43. Pteridine studies. Part VII. The degradation of 4-, 6-, and 7-hydroxypteridine by acid and alkali
44. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products
45. 1,1'-(Azodicarbonyl)dipiperidine-tributylphosphine, a new reagent system for Mitsnobu reaction
46. 2 receptor antagonists
47. Arylation of unsaturated compounds by diazonium salts (the Meerwein Arylation reaction)